Rapid mRNA Expression Analysis by Quantitative Electrochemical Microarray at Sub-Zeptomole Levels without PCR and Labels
Rapid mRNA Expression Analysis by Quantitative Electrochemical Microarray at Sub-Zeptomole Levels without PCR and Labels
批准号:
9556918
负责人:
Ravi Saraf
金额:
$28.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-05-01 至 2020-10-31
关键词:
AddressBindingBiological ProcessBiologyBody FluidsBuffersCalibrationCell LineCell physiologyCellsComplementary DNADataData QualityDetectionDiagnosticDiseaseDyesElectrochemistryElectrodesExpression ProfilingFine needle aspiration biopsyFluorescenceGene ExpressionGene MutationGenesGeneticGenomicsGoalsGoldHealthcareKineticsLabelLasersMeasurementMeasuresMediatingMedicineMessenger RNAMethodsMethylene blueMicroarray AnalysisMolecularNatural regenerationNatureNoiseNucleic AcidsNucleotidesOutcomeOxidation-ReductionPatternPerformancePhaseProcessRNARNA-Directed DNA PolymeraseReactionReadingResearchScanningSensitivity and SpecificitySignal TransductionSiteSpecificitySpeedSpottingsTechnologyTherapeuticTimeVariantbasegene discoveryinterestinventionlogarithmmRNA Expressionprognosticstatisticsstemsuccesstranscriptome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Methods for obtaining transcriptome data have revolutionized our understanding of biological processes and
disease dynamics at the fundamental level, impacting health care on all three fronts: diagnostics, prognostics,
and therapeutics. The compiling of transcriptome information, at one end of the spectrum leads to discovery of
genes and mutations using, for example, the Sanger method and NetGen sequencing, and at the other end of
the spectrum is the quantification of genetic expressions of known sequences using methods such as qPCR
and microarrays. The proposed research pertains to the quantification of gene expression at few cell levels.
Fundamental limitations of qPCR (the gold standard) and microarrays emerge from the inefficiencies and
errors inherent to two necessary processes: cDNA synthesis by reverse transcriptase (RT) reaction, that
requires more than 105 copies for reasonable efficiency, and subsequent PCR amplification, which may be
prone to errors in exact replication. The goal of the proposed research is to develop a technology that
eliminates these two processes and achieves at least an order of magnitude better sensitivity and better quality
data in terms of self-consistency and normalization to accurately estimate relative expression levels of targeted
mRNA. The expression level of 15 sequences from cell lines will be quantified simultaneously for this proof-of-
principle study. The technology to be used is based on three principle steps: (i) targeting two unique sites of ~
25 nucleotides on each mRNA of interest and exclusively separating the specifically bound target ssDNA
sequences (TRID process); (ii) binding the ssDNA targets to a microarray mediated by electrochemical redox
to obtain binding of ~ 1,800 molecules in 0.3 mL solution to microspots in less than 30 min at 100% specificity
(EREB process); and (iii) reading the binding electrochemically at a responsivity of 0.4 zeptomole of probe-
target binding to achieve a sensitivity of 10 attomolar and a dynamic range of five orders of magnitude (SEED
process). It is expected that the time to result (TTR) after RNA extraction will be less than 3 hr. Specific Aim
1: Calibration of the SEED signal. The SEED signal for ssDNA targets for each mRNA from 10 aM to 10 pM
in buffer will be measured to obtain calibration curves. The outcome will be the optimization of EREB to obtain
copy numbers of all of the mRNA on a single chip. Specific Aim 2: qPCR study. Two cell lines of known
dysregulation in genes will be cultured. The outcome will be mRNA expression of lysate of a known amount of
cells by qPCR for all of the genes. Specific Aim 3: Technology verification study. TRID, EREB, and SEED will
be performed at various dilutions of the same lysate solution used for qPCR. The outcome will be
determination of the LOD and ENMC and the ability to measure at least 1.5-fold changes in copy number
between the two cell lines and/or dilutions. Leveraging the high sensitivity and specificity, the long-term goal is
to develop a quantitative microarray technology for gene expression of a few cells for applications such as
single cell genomics, fine needle aspiration biopsy, and cell-free circulating nucleic acids.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Low-Cost, Handheld Tactile Imaging Device for Breast Cancer Screening
-
批准号:9465604
-
项目类别:
-
资助金额:$29.97万
-
财政年份:2017
-
负责人:Ravi Saraf
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: